[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].

P Cappelaere(European Organisation for Research and Treatment of Cancer), B Hecquet(Institut für Gießereitechnik), J M Pion, I. Krakowski, C. Domenge(Institut Gustave Roussy), C. De Gislain, J Chauvergne(European Organisation for Research and Treatment of Cancer), L Méeus, F. Dufour-Esquerré, F. Rolland(Institut de Cancérologie de l'Ouest), C. Fournier
PubMed
July 1, 1996
Cited by 0

Related Papers

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
|Blood|1994|581
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma
|British Journal of Cancer|2000|253
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
|PubMed|1998|114
LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
|Annals of Oncology|2021|87
Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study
|Journal of Clinical Oncology|2009|80